Should All Patients with Temporal Arteritis Receive Aspirin?
No, aspirin should not be routinely prescribed to all patients with giant cell arteritis (GCA), but should be added selectively for those with critical vascular involvement or flow-limiting stenosis.
Current Evidence-Based Approach
The recommendation regarding aspirin in GCA has evolved significantly based on newer evidence:
The 2021 ACR/Vasculitis Foundation Guideline Position 1, 2
The most recent and authoritative guideline conditionally recommends adding aspirin only for patients with GCA who have critical or flow-limiting involvement of the vertebral or carotid arteries (level of evidence: very low to moderate). This represents a significant departure from older blanket recommendations.
Why the Change from Universal Aspirin Use?
The 2018 EULAR update 3 explicitly reversed their earlier 2009 recommendation 4 that advocated universal low-dose aspirin (75-150 mg/day) for all GCA patients. Here's why:
- Original rationale (2009): Two retrospective studies suggested aspirin might reduce vision loss and stroke
- Updated evidence (2018): Two more recent cohort studies and a meta-analysis failed to confirm a protective effect of aspirin in GCA
- Risk-benefit analysis: The potential (but unproven) benefit must be weighed against real bleeding risks, especially given concurrent high-dose glucocorticoid therapy
The Evidence Gap
A 2014 Cochrane review 5 found zero randomized controlled trials meeting inclusion criteria for aspirin in GCA, confirming there is no high-quality evidence to support routine use. The review explicitly noted that clinicians must recognize established hemorrhagic risks with aspirin, particularly when combined with corticosteroids.
Clinical Algorithm for Aspirin Use in GCA
Add aspirin (75-100 mg daily) if:
- Critical stenosis of vertebral or carotid arteries documented on imaging
- Flow-limiting vascular involvement
- Acute ischemic complications (vision loss, stroke) have occurred
- Consider during the first month of treatment in high-risk patients 6
Do NOT routinely prescribe aspirin if:
- Uncomplicated cranial GCA without critical stenosis
- Increased bleeding risk (age >60, history of GI bleeding, concurrent anticoagulation)
- Other cardiovascular indications are absent
If aspirin IS used:
- Dose: 75-100 mg daily (not higher doses)
- Always provide gastroduodenal mucosal protection 4 given concurrent glucocorticoid therapy
- Duration: Consider limiting to first month unless ongoing vascular indication 6
Key Clinical Pitfalls
- Don't automatically prescribe aspirin based on older 2009 guidelines - the evidence base has changed
- Don't ignore bleeding risk - the combination of high-dose glucocorticoids plus aspirin significantly increases GI bleeding risk
- Do obtain vascular imaging when considering aspirin - the decision should be based on documented vascular involvement, not just the GCA diagnosis
- Consider individual cardiovascular risk factors - if the patient has separate indications for aspirin (coronary disease, prior stroke), then prescribe it for those reasons 3
Bottom Line
The shift from universal to selective aspirin use in GCA reflects modern evidence-based medicine: prescribe aspirin when there's documented critical vascular involvement or other clear cardiovascular indications, but not routinely for all GCA patients. The decision requires vascular imaging and individualized risk-benefit assessment, particularly given the hemorrhagic risks when combined with high-dose glucocorticoids.